Annals of Behavioral Medicine

, Volume 24, Issue 4, pp 336–344 | Cite as

Stress, coping, and immune function in breast cancer

Article

Abstract

Research has found suggestive links between emotional distress and immune and neuroendocrine measures in cancer patients. Furthermore, several studies have reported that participation in psychological support groups is associated with better health outcomes for cancer patients. However, controversy exists surrounding these findings, and the mechanisms behind such effects are unclear. This article integrates current evidence from several lines of research concerning the relations among coping, psychological adjustment, cortisol and immune function, and disease progression in breast cancer patients. A biopsychosocial model is evaluated in which coping and psychological adjustment are associated with alterations in cortisol levels, immune function, and potential long-term medical outcomes in breast cancer patients. Although strong evidence suggests that coping and psychosocial intervention can improve psychological outcomes for breast cancer patients, potential effects on physiological outcomes remain speculative.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1).
    American Cancer Society:Cancer Facts and Figures-1996. Atlanta, GA: American Cancer Society, 1996.Google Scholar
  2. (2).
    Andersen BL: Psychological interventions for cancer patients to enhance the quality of life.Journal of Consulting and Clinical Psychology. 1992,60:552–568.PubMedCrossRefGoogle Scholar
  3. (3).
    Carver CS, Pozo C, Harris SD, et al.: How coping mediates the effects of optimism on distress: Study of women with early stage breast cancer.Journal of Personality and Social Psychology. 1993,65:375–391.PubMedCrossRefGoogle Scholar
  4. (4).
    Epping-Jordan JE, Compas BE, Osowiecki D, et al.: Psychological adjustment in breast cancer: Processes of emotional distress.Health Psychology. 1999,18:315–326.PubMedCrossRefGoogle Scholar
  5. (5).
    Maes M: Evidence for an immune response in major depression: A review and hypothesis.Progress in Neuro-Psychopharmacology. 1995,19:11–38.CrossRefGoogle Scholar
  6. (6).
    Michelson D, Licinio J, Bold PW: Mediation of the stress response by the hypothalamic-pituitary-adrenal axis. In Friedman MJ, Charney DS, Deutch AY (eds),Neurobiological and Clinical Consequences of Stress. Philadelphia: Lippincott-Ra-ven, 1995, 225–238.Google Scholar
  7. (7).
    Andersen BL, Kiecolt-Glaser JK, Glaser R: A biobehavioral model of cancer stress and disease course.American Psychologist. 1994,49:389–404.PubMedCrossRefGoogle Scholar
  8. (8).
    Bovbjerg DH: Psychoneuroimmunology: Implications for oncology?Cancer. 1991,67:828–832.PubMedCrossRefGoogle Scholar
  9. (9).
    Spiegel D, Sephton SE, Terr AI, Stites DP: Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways.Annals of the New York Academy of Sciences. 1998,840:674–683.PubMedCrossRefGoogle Scholar
  10. (10).
    Fawzy FI, Fawzy NW, Hyun CS, et al.: Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later.Archives of General Psychiatry. 1993,50:681–689.PubMedGoogle Scholar
  11. (11).
    Spiegel D, Bloom JR, Kraemer HC, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer.Lancet. 1989,2:888–891.PubMedCrossRefGoogle Scholar
  12. (12).
    Maunsell E, Brisson J, Mondor M, Verreault R, Descehes L: Stressful life events and survival after breast cancer.Psychosomatic Medicine. 2001,63:306–315.PubMedGoogle Scholar
  13. (13).
    Hilakivi-Clarke L, Rowland J, Clarke R, Lippman ME: Psychosocial factors in the development and progression of breast cancer.Breast Cancer Research and Treatment. 1993,29:141–160.CrossRefGoogle Scholar
  14. (14).
    Sherbourne CD, Hays RD, Ordway L, DiMatteo MR, Kravitz RL: Antecedents of adherence to medical recommendations: Results from the Medical Outcomes Study.Journal of Behavioral Medicine. 1992,15:447–468.PubMedCrossRefGoogle Scholar
  15. (15).
    Maier SF, Watkins LR: Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition.Psychological Review. 1998,105:83–107.PubMedCrossRefGoogle Scholar
  16. (16).
    Yurke D, Farrar W, Andersen BL: Breast cancer surgery: Comparing surgical groups and determining individual differences in postoperative sexuality and body change stress.Journalof ConsultingandClinicalPsychology.2000,68:697–709.Google Scholar
  17. (17).
    Northouse LL, Templin T, Mood D, Oberst M: Couples’ adjustment to breast cancer and benign breast disease: A longitudinal analysis.Psycho-Oncology. 1998,7:37–48.PubMedCrossRefGoogle Scholar
  18. (18).
    Andrykowski MA, Cordova MJ, Studts JL, Miller TW: Posttraumatic stress disorder after treatment for breast cancer: Prevalence of diagnosis and use of the PTSD Checklist-Civilian Version (PCL-C) as a screening instrument.Journal of Consulting and Clinical Psychology. 1998,66:586–590.PubMedCrossRefGoogle Scholar
  19. (19).
    Cordova MJ, Andrykowski MA, Kenady DE, et al.: Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for breast cancer.Journal of Consulting and Clinical Psychology. 1995,63:981–986.PubMedCrossRefGoogle Scholar
  20. (20).
    Compas BE, Stoll MF, Thomsen AH, et al.: Adjustment to breast cancer: Age-related differences in coping and emotional distress.BreastCancer ResearchandTreatment.1999,54:195–203.Google Scholar
  21. (21).
    Vinocur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA: The process of recovery from breast cancer for younger and older patients: Changes during the first year.Cancer. 1990,65:1242–1254.CrossRefGoogle Scholar
  22. (22).
    Bleiker EM, Pouwer F, van der Ploeg HM, Leer JW, Ader HJ: Psychological distress two years after diagnosis of breast cancer: Frequency and prediction.Patient Education and Counseling. 2000,40:197–199.CrossRefGoogle Scholar
  23. (23).
    Primo K, Compas BE, Oppedisano G, et al.: Intrusive thoughts and avoidance in breast cancer: Individual differences and association with psychological distress.Psychology and Health. 1999,15:1–13.Google Scholar
  24. (24).
    Vickberg SM, Bovbjerg DH, DuHamel KN, Currie V, Redd WH: Intrusive thoughts and psychological distress among breast cancer survivors: Global meaning as a possible protective factor.Behavioral Medicine. 2000,25:152–160.PubMedCrossRefGoogle Scholar
  25. (25).
    Schwartz MD, Lerman C, Miller SM, Daly M, Masny A: Coping disposition, perceived risk, and psychological distress among women at increased risk for ovarian cancer.Health Psychology. 1995,14:232–235.PubMedCrossRefGoogle Scholar
  26. (26).
    Compas BE, Connor JK, Osowiechi DN, Welch A: Effortful and involuntary responses to stress: Implications for coping with chronic stress. In Gottlieb B (ed),Coping with Chronic Stress. New York: Plenum, 1997, 105–132.Google Scholar
  27. (27).
    Connor JK, Compas BE, Wadsworth ME, Thomsen AH, Saltzman H: Responses to stress in adolescence: Measurement of coping and involuntary stress responses.Journal of Consulting and Clinical Psychology. 2000,68:976–992.CrossRefGoogle Scholar
  28. (28).
    McCaul K, Sandgren AK, King B, et al.:Copingand adjustmenttobreastcancer.Psycho-Oncology.1999,8:230–236.PubMedCrossRefGoogle Scholar
  29. (29).
    Stanton AL, Snider PR: Coping with a breast cancer diagnosis:Aprospectivestudy.HealthPsychology.1993,12:16–23.Google Scholar
  30. (30).
    Schnoll RA, Harlow LL, Stolbach LL, Brandt U: A structural model of the relationships among stage of disease, age, coping, and psychological adjustment in women with breast cancer.Psycho-Oncology. 1998,7:69–77.PubMedCrossRefGoogle Scholar
  31. (31).
    Epping-Jordan JE, Compas BE, Howell D: Predictors of cancer progress in young adult men and women: Avoidance, intrusive thoughts, and psychological symptoms.Health Psychology. 1994,13:539–547.PubMedCrossRefGoogle Scholar
  32. (32).
    Reynolds P, Hurley S, Torres M, et al.: Use of coping strategies and breast cancer survival: Results from the Black/White Cancer Survival Study.American Journal of Epidemiology. 2000,152:940–949.PubMedCrossRefGoogle Scholar
  33. (33).
    Kathol RG, Anton R, Noyes R, Gehris T: Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder.Biological Psychiatry. 1989,25:873–878.PubMedCrossRefGoogle Scholar
  34. (34).
    Yehuda R, Boisoneau D, Mason JW, Giller EL: Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders.Biological Psychiatry. 1993,34:18–25.PubMedCrossRefGoogle Scholar
  35. (35).
    Stratakis CA, Chrousos GP:Neuroendocrinologyand pathophysiology of the stress system.Annals of the New York Academy of Science. 1995,771:1–18.CrossRefGoogle Scholar
  36. (36).
    O’Leary A: Stress, emotion, and human immune function.Psychological Bulletin. 1990,108:363–382.PubMedCrossRefGoogle Scholar
  37. (37).
    Banu N, Vaidya MP, Udupa KN: Alterations in circulating neurotransmitters and cortisol with severity of breast cancer.Indian Journal of Medical Research. 1988,87:479–483.PubMedGoogle Scholar
  38. (38).
    Bryla CM: The relationship between stress and the development of breast cancer: A literature review.Oncology Nursing Forum. 1996,23:441–448.PubMedGoogle Scholar
  39. (39).
    Kronfol Z, Nair M, Zhang Q, Hill EE, Brown MB: Circadian immune measures in healthy volunteers: Relationship to hypo-thalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters.Psychosomatic Medicine. 1997,59:42–50.PubMedGoogle Scholar
  40. (40).
    Lippman ME: Psychosocial factors and the hormonal regulation of tumor growth. In Levy SM (ed),Behavior and Cancer. San Francisco: Jossey-Bass, 1985, 134–147.Google Scholar
  41. (41).
    Herbert TB, Cohen S: Depression and immunity: A metaanalytic review.Psychological Bulletin. 1993,113:472–486.PubMedCrossRefGoogle Scholar
  42. (42).
    Herbert TB, Cohen S: Stress and immunity in humans: A meta-analytic review.Psychosomatic Medicine. 1993,55:364–379.PubMedGoogle Scholar
  43. (43).
    Weisse CS: Depression and immunocompetence: A review of the literature.Psychological Bulletin. 1992,111:475–489.PubMedCrossRefGoogle Scholar
  44. (44).
    Kronfol Z, House DJ, Silva J, Greden J, Carroll BJ: Depression, urinary free cortisol excretion, and lymphocyte function.British Journal of Psychiatry. 1986,148:70–73.PubMedCrossRefGoogle Scholar
  45. (45).
    Schleiffer SJ, Keller SE, Meyerson AT, et al.: Lymphocyte proliferation in major depressive disorder.Archives of General Psychiatry. 1984,41:484–486.Google Scholar
  46. (46).
    Caldwell C, Irwin L, Lohr M: Reduced natural killer cell cytotoxicity in depression but not in schizophrenia:Biological Psychiatry. 1991,31:1131–1138.CrossRefGoogle Scholar
  47. (47).
    Maes M, Stevens W, Peeters D, et al.: A study on the blunted natural killer cell activity in severely depressed patients.Life Science. 1992,50:505–513.CrossRefGoogle Scholar
  48. (48).
    Nerozzi D, Santoni A, Bersani G: Reduced natural killer cell activity in major depression: Neuroendocrine implications.Psychoneuroendorinology. 1989,14:295–301.CrossRefGoogle Scholar
  49. (49).
    Andersen BL, Farrar WB, Golden-Kreutz D, et al.: Stress and immune responses after surgical treatment for regional breast cancer.Journal of the National Cancer Institute. 1998,90:30–36.PubMedCrossRefGoogle Scholar
  50. (50).
    Sachs G, Rasoul-Rockenschaub S, Aschauer H, et al.: Lytic effector cell activity and major depressive disorder in patients withbreastcancer:Aprospectivestudy.Journalof Neuroimmunology. 1995,59:83–89.CrossRefGoogle Scholar
  51. (51).
    Fredrikson M, Furst CJ, Lekander M, Rotstein S, Blomgren H: Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.Brain, Behavior, and Immunity. 1993,7:79–90.PubMedCrossRefGoogle Scholar
  52. (52).
    Tjemsland L, Soreide JA, Matre R, Malt UF: Pre-operative psychological variables predict immunological status in patients withoperablebreastcancer.Psycho-Oncology.1997,6:311–320.PubMedCrossRefGoogle Scholar
  53. (53).
    Manyande A, Berg S, Gettins D, et al.: Preoperative rehearsal of active coping imagery influences subjective and hormonal responses to abdominal surgery.Psychosomatic Medicine. 1995,57:177–182.PubMedGoogle Scholar
  54. (54).
    Ehlert U, Patalla U, Kirschbaum C, Piedmont E, Hellhammer DH: Postpartum blues: Salivary cortisol and psychological factors.JournalofPsychosomaticResearch. 1990,34:319–325.Google Scholar
  55. (55).
    Goodkin K, Blaney NT, Feaster D, et al.: Active coping style is associated with natural killer cell cytotoxicity in asymptomatic HIV-1 seropositive homosexual men.Journal of Psychosomatic Research. 1992,36:635–650.PubMedCrossRefGoogle Scholar
  56. (56).
    Goodkin K, Fuchs I, Feaster D, Leeka J, Rishel DD: Life stress-ors and coping style are associated with immune measures in HIV-1 infection—a preliminary report.International Journal of Psychiatry and Medicine. 1992,22:155–172.CrossRefGoogle Scholar
  57. (57).
    Ironson G, Friedman A, Klimas N, et al.: Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus.International Journal of Behavioral Medicine. 1994,1:90–105.PubMedCrossRefGoogle Scholar
  58. (58).
    Futterman AD, Wellisch DK, Zighelboim J, Luna-Raines M, Weiner H: Psychological and immunological reactions of family members to patients undergoing bone marrow transplantation.Psychosomatic Medicine. 1996,58:472–480.PubMedGoogle Scholar
  59. (59).
    Fawzy FI, Kemeny ME, Fawzy NW, et al.: A structured psychiatric intervention for cancer patients II: Changes over time in immunological measures.Archives of General Psychiatry. 1990,47:729–735.PubMedGoogle Scholar
  60. (60).
    Levy SM, Herberman RB, Whiteside T, Sanzo K, Lee J, Kirkwood J: Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients.Psychosomatic Medicine. 1990,52:73–85.PubMedGoogle Scholar
  61. (61).
    Turner-Cobb JM, Sephton SE, Koopman C, Blake-Mortimer J, Spiegel D: Social support and salivary cortisol in women with metastatic breast cancer.Psychosomatic Medicine. 2000,62:337–345.PubMedGoogle Scholar
  62. (62).
    Maunsell E, Brisson J, Deschenes L: Social support and survivalamongwomenwithbreastcancer.Cancer. 1995,76:631–637.PubMedCrossRefGoogle Scholar
  63. (63).
    Barraclough J, Pinder P, Cruddas M, et al.: Life events and breastcancer prognosis.British Medical Journal. 1992,304:1078–1081.PubMedGoogle Scholar
  64. (64).
    Ramirez AJ, Craig TKJ, Watson JP, et al.: Stress and relapse of breast cancer.British Medical Journal. 1989,298:291–293.PubMedGoogle Scholar
  65. (65).
    Hilakivi-Clarke L: Estrogen-regulated non-reproductive behaviors and breast cancer risk: Animal models and human studies.Breast Cancer Research and Treatment. 1997,46:143–159.PubMedCrossRefGoogle Scholar
  66. (66).
    Richards JE, Edery M, Osborn RC, Larson LN, Nandi S: Effect of hormones and epidermal growth factor on the growth of the hormone-responsive 13762NF rat mammary tumor in collagen gel culture.Journal of the National Cancer Institute. 1986,76:669–682.PubMedGoogle Scholar
  67. (67).
    Simon WE, Albrecht M, Trams G, Dietel M, Holzel F: In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin.Journal of the National Cancer Institute. 1984,73:313–320.PubMedGoogle Scholar
  68. (68).
    Lippman ME, Bolan G, Huff K: The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer inlong-termtissueculture.CancerResearch. 1976,36:4602–4609.Google Scholar
  69. (69).
    Steffen M, Scherdin U, Duvigneau C, Holzel F: Gluco-corticoid-induced alterations of morphology and growth of fibrosarcoma cells derived from 7,12-dimethylbenz(a)antra-ceneratmammarytumor.CancerResearch. 1988,48:7212–7218.Google Scholar
  70. (70).
    Hiraoka D, Nakamura N, Nishizama Y, et al.: Inhibitory and stimulatory effects of glucocorticoid on androgen-induced growth of murine Shionogi carcinoma 115 in vivo and in cell culture.Cancer Research. 1987,47:6560–6564.PubMedGoogle Scholar
  71. (71).
    van der Pompe G, Antoni MH, Heijnen CJ: Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer.Psychoneuroendocrinology. 1996,21:361–374.PubMedCrossRefGoogle Scholar
  72. (72).
    van der Pompe G, Duivenvoorden HJ, Antoni MH, Visser A, Heijnen CJ: Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients.Journal of Psychosomatic Research. 1997,42:453–466.PubMedCrossRefGoogle Scholar
  73. (73).
    Touitou Y, Bogdan A, Levi F, Benavides M, Auzeby A: Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: Relationships with tumour marker antigens.British Journal of Cancer. 1996,74:1248–1252.PubMedGoogle Scholar
  74. (74).
    Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D: Diurnal cortisol rhythm as a predictor of breast cancer survival.Journal of the National Cancer Institute. 2000,92:993–1000.CrossRefGoogle Scholar
  75. (75).
    Baxevanis CN, Reclos GJ, Gritzapis AD, et al.: Elevated prosta-glandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.Cancer. 1993,72:491–501.PubMedCrossRefGoogle Scholar
  76. (76).
    Kundu N, Fulton AM: Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis.Cellular Immunology. 1997,180:55–61.PubMedCrossRefGoogle Scholar
  77. (77).
    Lytle GH: Immunotherapy of breast cancer: A review of the development of cell-specific therapy.Seminars in Surgical Oncology. 1991,7:211–216.PubMedCrossRefGoogle Scholar
  78. (78).
    Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer.Current Opinions in Immunology. 1995,7:704–710.CrossRefGoogle Scholar
  79. (79).
    Greenberg PD: Mechanisms of tumor immunology. In Stites DP, Terr AI (eds),Basic and Clinical Immunology. Norwalk, CT: Appleton and Lange, 1991, 580–587.Google Scholar
  80. (80).
    Jerome KR, Barnd DL, Bendy KM, et al.: Cytotoxic T lymphocytes from patients with breast Gleevac adenocarcinoma recognize an epitope present on the core peptide of a mucin molecule preferentially expressed by malignant cells.Cancer Research. 1991,51:2908–2916.PubMedGoogle Scholar
  81. (81).
    Yamasaki S, Kan N, Harada T, et al.: Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immunotherapy.Breast Cancer Research and Treatment. 1993,26:55–65.PubMedCrossRefGoogle Scholar
  82. (82).
    Levy SM, Herberman R, Lippman M, D∉Angelo T: Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer.Journal of Clinical Oncology. 1987,5:348–353.PubMedGoogle Scholar
  83. (83).
    Levy SM, Herberman RB, Lippman M, D’Angelo T, Lee J: Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer.Behavioral Medicine. 1991,17:67–75.PubMedCrossRefGoogle Scholar
  84. (84).
    Wiltschke C, Tyl E, Speiser P, et al.: Increased natural killer activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.Cancer. 1993,73:135–139.CrossRefGoogle Scholar
  85. (85).
    Eremin O, Ashby J, Stephens JP: Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease.International Journal of Cancer. 1978,21: 35–41.CrossRefGoogle Scholar
  86. (86).
    Shevde LA, Narendra NJ, Shinde SR, Nadkarni JJ: Studies on functional status of circulating lymphocyte in unaffected membersfromcancerfamilies.HumanImmunology.1998,59:373–381.Google Scholar
  87. (87).
    Akimoto M, Ishii H, Nakajima Y, et al.: Assessment of host immune response in breast cancer patients.Cancer Detection and Prevention. 1986,9:311–317.PubMedGoogle Scholar
  88. (88).
    Guckel B, Lindauer M, Rudy W, et al.: CD80-transfected humanbreastandovariantumorcelllines:Improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.Cytokines and Molecular Therapy. 1995,1:211–221.PubMedGoogle Scholar
  89. (89).
    Head JF, Elliott RL, McCoy JL: Evaluation of lymphocyte immunity in breast cancer patients.Breast Cancer Research and Treatment. 1993,26:77–88.PubMedCrossRefGoogle Scholar
  90. (90).
    Wiltschke C, Krainer M, Budinsky AC, et al.: Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: A prospective longitudinal study.British Journal of Cancer. 1995,71:1292–1296.PubMedGoogle Scholar
  91. (91).
    Burford-Mason A, Gyte GM, Watkins SM: Phytohaemag-glutinin responsiveness of peripheral lymphocytes and survival in patients with primary breast cancer.Breast Cancer Research and Treatment. 1989,31:243–250.CrossRefGoogle Scholar
  92. (92).
    Hacene K, Desplaces A, Brunet M, et al.: Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer.Cancer. 1986,57:245–250.PubMedCrossRefGoogle Scholar
  93. (93).
    Garner WL, Minton JP, James AG, Hoffmann CC: Human breast cancer and impaired NK cell function.Journal of Surgical Oncology. 1983,24:64–66.PubMedCrossRefGoogle Scholar
  94. (94).
    Meyer TJ, Mark MM: Effects of psychosocial interventions with adult cancer patients: A meta-analysis of randomized experiments.Health Psychology. 1995,14:101–108.PubMedCrossRefGoogle Scholar
  95. (95).
    Fawzy FI, Fawzy NW, Arndt LA, Pasnau RO: Critical review of psychosocial interventions in cancer care.Archives of General Psychiatry. 1995,52:100–113.PubMedGoogle Scholar
  96. (96).
    Helgeson VS, Cohen S: Social support and adjustment to cancer: Reconciling descriptive, correlational, and intervention research.Health Psychology. 1996,15:135–148.PubMedCrossRefGoogle Scholar
  97. (97).
    Trijsburg RW, van Knippenberg CE, Rijpma SE: Effects of psychological treatment on cancer patients: A critical review.Psychosomatic Medicine. 1992,54:489–517.PubMedGoogle Scholar
  98. (98).
    Classen C, Butler LD, Koopman C, et al.: Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial.Archives of General Psychiatry. 2001,58:494–501.PubMedCrossRefGoogle Scholar
  99. (99).
    Goodwin PJ, Leszcz M, Ennix M, et al.: The effect of group psychosocial support on survival in metastatic breast cancer.The New England Journal of Medicine. 2001,345:1719–1726.PubMedCrossRefGoogle Scholar
  100. (100).
    Cruess S, Antoni M, Cruess D, et al.: Reductions in herpes simplex virus type 2 antibody titers after cognitive behavioral stress management and relationships with neuroendocrine function, relaxation skills, and social support in HIV-positive men.Psychosomatic Medicine. 2000,62: 828–837.PubMedGoogle Scholar
  101. (101).
    Antoni MH, Cruess S, Cruess DG, et al.: Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men.Annals of Behavioral Medicine. 2000,22:29–37.PubMedGoogle Scholar
  102. (102).
    Davis H: Effects of biofeedback and cognitive therapy on stress in patients with breast cancer.Psychological Reports. 1986,59:967–974.PubMedGoogle Scholar
  103. (103).
    Schedlowski M, Jung C, Schimanski G, Tewes U, Schmoll HJ: Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: An exploratory study.Psychooncology. 1994,3:181–187.CrossRefGoogle Scholar
  104. (104).
    Gruber BL, Hersh SP, Hall NRS, et al.: Immunological responses of breast cancer patients to behavioral interventions.Biofeedback and Self-Regulation. 1993,18:1–22.PubMedCrossRefGoogle Scholar
  105. (105).
    Cruess DG, Antoni MH, McGregor BA, et al.: Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit-finding among women being treated for early stagebreastcancer.PsychosomaticMedicine. 2000,62:304–308.Google Scholar
  106. (106).
    Hosaka T, Tokuda Y, Sugiyama Y, Hirai K, Okuyama T: Effects of a structured psychiatric intervention on immune function of cancer patients.Tokai Journal of Experimental Clinical Medicine. 2000,25:183–188.Google Scholar
  107. (107).
    Grossarth-Maticek R, Eysenck HJ: Length of survival and lymphocyte percentage in women with mammary cancer as a functionofpsychotherapy.PsychologicalReports. 1989,65:315–321.Google Scholar
  108. (108).
    Fox BH: Quandaries created by unlikely numbers in some of Grossarth-Maticek’sstudies.Psychological Inquiry. 1991,2:242–247.CrossRefGoogle Scholar
  109. (109).
    Edelman S, Lemon J, Bell DR, Kidman AD: Effects of group CBT on the survival time of patients with metastatic breast cancer.Psycho-Oncology. 1999,8:474–481.PubMedCrossRefGoogle Scholar
  110. (110).
    Cunningham AJ, Edmonds CVI, Jenkins GP, et al.: A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer.Psycho-Oncology. 1998,7:508–517.PubMedCrossRefGoogle Scholar
  111. (111).
    Gellert GA, Maxwell RM, Siegel BS: Survival of breast cancer patients receiving adjunctive psychosocial support therapy: A 10-year follow-up study.Journal of Clinical Oncology. 1993,11:66–69.PubMedGoogle Scholar
  112. (112).
    Compas BE, Connor JK, Saltzman H, Thomsen AH, Wads-worth ME: Coping with stress during childhood and adolescence: Problems, progress, and potential in theory and research.Psychological Bulletin. 2001,127:87–127.PubMedCrossRefGoogle Scholar
  113. (113).
    Compas BE, Haaga DF, Keefe F, Leitenberg H, Williams DA: Sampling of empirically supported interventions from health psychology and behavioral medicine: Smoking, chronic pain, cancer, and bulimia nervosa.Journal of Consulting and Clinical Psychology. 1998,66:89–112.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Behavioral Medicine 2002

Authors and Affiliations

  1. 1.Department of PsychologyArizona State UniversityTempe
  2. 2.The University of VermontUK

Personalised recommendations